Skip to main content
    D

    DiaMedica Therapeutics Inc (DMAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.25
    -0.27 (-2.84%)

    Market Cap: $498.81M

    Last updated: Oct 30, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(24/37)
    Avg Surprise
    +1.66%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.23 - $-0.19
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.21+2.4%
    60d ago$-0.21+2.4%
    30d ago$-0.210.0%
    7d ago$-0.210.0%
    Current$-0.21
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.29 - $-0.17
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.22---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 10
    		$-0.19$-0.19+0.00%Beat-5.6%
    Mar 26
    Reported May 6
    		$-0.19$-0.18-5.56%Miss-5.6%
    Dec 25
    Reported Mar 30
    		$-0.17$-0.17+2.86%Beat+5.6%
    Sep 25
    Reported Nov 12
    		$-0.17$-0.16-6.25%Miss-13.3%
    Jun 25
    Reported Aug 12
    		$-0.18$-0.19+5.26%Beat-38.5%
    Mar 25
    Reported May 13
    		$-0.18$-0.18+0.00%Beat-28.6%
    Dec 24
    Reported Mar 17
    		$-0.18$-0.17-4.35%Miss-28.6%
    Sep 24
    Reported Nov 13
    		$-0.15$-0.15+0.00%Beat-25.0%
    Jun 24
    Reported Aug 7
    		$-0.13$-0.16+18.75%Beat+18.8%
    Mar 24
    Reported May 8
    		$-0.14$-0.16+12.50%Beat+30.0%
    Dec 23
    Reported Mar 19
    		$-0.14$-0.14+0.00%Beat+0.0%
    Sep 23
    Reported Nov 13
    		$-0.12$-0.13+7.69%Beat+0.0%
    Jun 23
    Reported Aug 14
    		$-0.16$-0.18+11.11%Beat-23.1%
    Mar 23
    Reported May 15
    		$-0.20$-0.16-25.00%Miss-53.8%
    Dec 22
    Reported Mar 28
    		$-0.14$-0.14+0.00%Beat-27.3%
    Sep 22
    Reported Nov 9
    		$-0.12$-0.15+20.00%Beat+33.3%
    Jun 22
    Reported Aug 10
    		$-0.13$-0.18+27.78%Beat+23.5%
    Mar 22
    Reported May 4
    		$-0.13$-0.21+38.10%Beat+31.6%
    Dec 21
    Reported Mar 14
    		$-0.11$-0.18+38.89%Beat+52.2%
    Sep 21
    Reported Nov 10
    		$-0.18$-0.23+21.74%Beat+5.3%
    Jun 21
    Reported Aug 11
    		$-0.17$-0.22+22.73%Beat+0.0%
    Mar 21
    Reported May 5
    		$-0.19$-0.22+13.64%Beat+0.0%
    Dec 20
    Reported Mar 10
    		$-0.23$-0.17-35.29%Miss-9.5%
    Sep 20
    Reported Nov 4
    		$-0.19$-0.15-26.67%Miss+5.0%
    Jun 20
    Reported Aug 11
    		$-0.17$-0.13-30.77%Miss+19.0%
    Mar 20
    Reported May 13
    		$-0.19$-0.28+32.14%Beat+29.6%
    Dec 19
    Reported Mar 23
    		$-0.21$-0.25+16.00%Beat+8.7%
    Sep 19
    Reported Nov 13
    		$-0.20$-0.21+4.76%Beat-185.7%
    Jun 19
    Reported Aug 13
    		$-0.21$-0.26+19.23%Beat+65.0%
    Mar 19
    Reported May 13
    		$-0.27$-0.20-35.00%Miss-35.0%
    Dec 18
    Reported Mar 19
    		$-0.23$-0.20-15.00%Miss-35.3%
    Sep 18
    Reported Nov 19
    		$-0.07N/A+56.25%Beat+65.0%
    Jun 18
    Reported Aug 29
    		$-0.60$-0.16-275.00%Miss-400.0%
    Mar 18
    Reported Apr 30
    		$-0.20$-0.16-25.00%Miss-
    Sep 17
    Reported Nov 27
    		$-0.17$-0.16-6.25%Miss-
    Jun 17
    Reported Aug 29
    		$-0.20$-0.14-42.86%Miss-
    Mar 17
    Reported Apr 27
    		$0.20$-0.16+225.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-12.85EV/EBITDAN/A
    Price/FCF-15.80xFCF Yield-6.33%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-114.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.72xQuick Ratio6.72x
    Trading Statistics
    Beta0.91Avg Volume225.88K
    52-Week High$10.4252-Week Low$5.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.86
    SMA 20$8.44
    SMA 50$7.61
    SMA 200$7.11
    EMA 10$8.93
    EMA 20$8.55
    EMA 50$7.89
    EMA 200$7.09

    MACD

    Line: 0.46Signal: 0.37Hist: 0.09

    ADX

    ADX: 33.6+DI: 33.0-DI: 15.8

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$8.10

    Bollinger Bands

    Upper Band$9.64
    Lower Band$7.23
    %B Position2856%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    63.0

    Momentum Oscillators

    Stoch %K76.7
    Stoch %D81.2
    Williams %R-34.1
    ROC (10d)22.2%
    Momentum1.68
    CCI (20d)132.2
    MFI (14d)55.2

    Volatility Measures

    ATR (14d)$0.54(5.8%)
    StdDev (20d)0.60
    Hist Vol74.7%(High)

    Volume Flow

    VWAP$9.30
    OBV13.6M
    AD Line-3.0M
    CMF (20d)-0.012

    Volume Metrics

    Avg Vol (20d)220.0K
    Vol Ratio0.8x
    VWMA (20d)$8.47

    Pivot Points

    R3$10.45
    R2$10.22
    R1$9.87
    Pivot Point$9.64
    S1$9.29
    S2$9.06
    S3$8.71

    Advanced Oscillators

    TSI28.15
    Ultimate Osc57.6
    KST177.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-27,999$0$0$0$13.80M$0$0$0$30.84M$0
    Cost of Revenue$0$0$13,999$0$0$0$11,000$0$0$0$8,000$0
    Gross Profit$0$0$-13,999$0$0$0$-11,000$0$0$0$-8,000$0
    Operating Expenses$10.50M$10.48M$9.21M$9.03M$8.01M$8.14M$8.42M$6.88M$5.64M$5.74M$5.85M$5.16M
    R&D$8.15M$7.99M$6.70M$6.44M$5.82M$5.66M$6.47M$4.98M$3.93M$3.68M$3.68M$3.27M
    SG&A$2.35M$2.50M$2.51M$2.60M$2.19M$2.49M$1.95M$1.90M$1.71M$2.06M$2.17M$1.89M
    Operating Income$-10,498,000$-10,482,000$-9,213,000$-9,033,000$-8,007,000$-8,144,000$-8,419,000$-6,883,000$-5,638,000$-5,741,000$-5,848,000$-5,157,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-10,132,000$-10,035,000$-8,730,000$-8,614,000$-7,693,000$-7,701,000$-7,891,000$-6,267,000$-5,112,000$-5,144,000$-5,139,000$-4,464,000
    Income Tax Expense$7,000$7,000$10,000$6,000$6,000$6,000$9,000$7,000$7,000$7,000$22,000$7,000
    Net Income$-10,139,000$-10,042,000$-8,740,000$-8,620,000$-7,699,000$-7,707,000$-7,900,000$-6,274,000$-5,119,000$-5,151,000$-5,161,000$-4,471,000
    EBITDA$-10,289,000$-10,214,000$-8,971,000$-8,845,000$-7,870,000$-7,951,000$-8,210,000$-6,622,000$-5,421,000$-5,465,000$-5,498,000$-4,880,000
    EBIT$-10,132,000$-10,035,000$-8,730,000$-8,614,000$-7,693,000$-7,701,000$-7,891,000$-6,267,000$-5,112,000$-5,144,000$-5,139,000$-4,464,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DMAC

    News

    DiaMedica Therapeutics Inc. (DMAC) Seasonal Returns Chart - Yahoo Finance

    This article from Yahoo Finance provides a seasonal returns chart for DiaMedica Therapeutics Inc. (DMAC). It displays the average monthly price return for the company's stock between 2016 and 2026...

    Yahoo! Finance Canada•10/30/26•Neutral

    (DMAC) Volatility Zones as Tactical Triggers

    This article analyzes Diamedica Therapeutics Inc. (NASDAQ: DMAC), noting neutral near-term readings but strong mid-term sentiment that may be stalling. It highlights no remaining resistance levels above the current...

    Stock Traders Daily•10/27/26•Neutral

    DiaMedica Therapeutics Inc. Estimates – NASDAQ:DMAC

    This article provides an overview of DiaMedica Therapeutics Inc. (NASDAQ: DMAC) financials and estimates on TradingView. It allows users to explore reported financial data, analyst estimates across various statements...

    TradingView•10/25/26•Neutral

    DiaMedica Therapeutics Inc. (DMAC) Stock Price, News, Quote & History

    DiaMedica Therapeutics Inc. (DMAC) closed at $8.63, down 0.69%, on October 22nd. The company, a clinical-stage biopharmaceutical firm, is focused on developing treatments for severe ischemic diseases...

    Yahoo! Finance Canada•10/22/26•Neutral

    DiaMedica Therapeutics reaches 200 patients in pivotal stroke trial

    DiaMedica Therapeutics has enrolled 200 patients in its pivotal ReMEDy2 stroke trial, reaching two-thirds of the minimum 300-patient target. An independent monitoring board will review the study after the first 200...

    Mugglehead Investment Magazine•10/22/26•Somewhat-Bullish

    DMAC Valuation and Fair Value

    P/E
    -12.8x
    P/FCF
    -15.8x
    P/B
    13.0x
    See GNG's fair value

    DMAC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -114.6%
    FCF yield
    -6.3%

    DMAC Competitors

    CompanyTicker
    CytomX Therapeutics IncCTMX
    Delcath Systems IncDCTH
    Ovid Therapeutics IncOVID
    Evolus IncEOLS
    AngioDynamics IncANGO
    Avita Medical LtdRCEL
    National Research CorpNRC
    Gyre Therapeutics Inc.GYRE

    Sector: Healthcare

    DMAC Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    DMAC Bull Case vs Bear Case

    Bull case

    • 100.0% of DMAC's analyst ratings are Buy or Strong Buy.

    Bear case

    • DMAC beat EPS estimates in 25.0% of its last 8 reported quarters.

    DMAC Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -1.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About DMAC

    Does DMAC pay dividends?

    DiaMedica Therapeutics Inc (DMAC) does not currently pay a regular dividend.

    What is DMAC's market cap?

    DiaMedica Therapeutics Inc (DMAC) has a market capitalization of $498.81M with a current stock price of $9.25.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In